Number of reported Counterfeits on the Rise
Recommendation

22 October 2026
Good Distribution Practice of Active Substances for Human and Veterinary Medicinal Products
The Drug Commission of German Pharmacists ("Arzneimittelkommission der Deutschen Apotheker", AMK) has published data from the year 2017 on notifications on quality deficiencies and adverse (drug) reactions on the AMK website.
The AMK received more notifications from pharmacies in 2017 than ever before. The Berlin based office received a total of 9084 reports from 4816 different pharmacies (for comparison: in 2016, there were 8891 reports and in 2015, there were 8409 reports on quality deficiencies and adverse reactions in total).
About 96% of all notifications were related to medicinal products. The most common cause for complaint was suspected cases of quality deficiencies (70%), followed by galenic deficiencies, mechanical defects and declaration errors. There was a significant rise in reported suspicions of manipulation and counterfeits: the number rose to overall 57 notifications in 2017 (from 14 in the year before). This doesn't necessarily mean an increasing number of counterfeits. It does also show a greater awareness for the issue, however.
The AMK doesn't only receive notifications from pharmacies; it also informs them about measures for the prevention of drug risks. However, incidents concerning medical devices are no longer recorded by the AMK. The complete AMK figures as well as a fact report can be found on the AMK website (in German language).
Related GMP News
30.09.2026European GDP Association Developments May through August 2026
30.09.2026Warehouse Temperature Excursions: What Does the FDA Expect?
30.09.2026Version 4.0 of the Swissmedic Document on Notifications of Changes Published
30.09.2026USA: Court Stops Warehouse Activities Following Persistent Insanitary Warehouse Conditions
30.09.2026GDP Non-Compliance Report: CAPA Measures must not only be Promised but also Implemented
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September


